Hey there

CCO Official Conference Coverage

2006 International AIDS Conference

August 13-18, 2006 | Toronto, Canada

First-Line Therapy and Switch Strategies

Track 1 of 8
Capsule Summaries
Expert Analysis

The following apply to the conference in its entirety and not to this specific track.

CCO Expert Recap

Faculty:

David A. Cooper, MD, DScJoel E. Gallant, MD, MPHKimberly Y. Smith, MD, MPH
  • David A. Cooper, MD, DSc
  • Joel E. Gallant, MD, MPH
  • Kimberly Y. Smith, MD, MPH

Resistance and Management of Treatment-Experienced Patients

Track 2 of 8
Capsule Summaries
Expert Analysis

The following apply to the conference in its entirety and not to this specific track.

CCO Expert Recap

Faculty:

Charles Boucher, MD, PhDKathleen E. Squires, MDMark A. Wainberg, PhD
  • Charles Boucher, MD, PhD
  • Kathleen E. Squires, MD
  • Mark A. Wainberg, PhD
Andrew R. Zolopa, MD
  • Andrew R. Zolopa, MD

New Agents and Insights from Basic Science

Track 3 of 8
Capsule Summaries
Expert Analysis

The following apply to the conference in its entirety and not to this specific track.

CCO Expert Recap

Faculty:

Pedro Cahn, MD, PhDJoseph J. Eron, Jr., MDDaniel R. Kuritzkes, MD
  • Pedro Cahn, MD, PhD
  • Joseph J. Eron, Jr., MD
  • Daniel R. Kuritzkes, MD

Clinical Pharmacology and Adverse Events

Track 4 of 8
Capsule Summaries
Expert Analysis

The following apply to the conference in its entirety and not to this specific track.

CCO Expert Recap

Faculty:

Terrence F. Blaschke, MDCharles Boucher, MD, PhDWilliam G. Powderly, MD
  • Terrence F. Blaschke, MD
  • Charles Boucher, MD, PhD
  • William G. Powderly, MD

Metabolic Complications and Lipodystrophy

Track 5 of 8
Capsule Summaries
Expert Analysis

The following apply to the conference in its entirety and not to this specific track.

CCO Expert Recap

Faculty:

Judith S. Currier, MD, MScDonald P. Kotler, MDJens D. Lundgren, MD, DMSc
  • Judith S. Currier, MD, MSc
  • Donald P. Kotler, MD
  • Jens D. Lundgren, MD, DMSc

Hepatitis and Opportunistic Coinfections

Track 6 of 8
Capsule Summaries
Expert Analysis

The following apply to the conference in its entirety and not to this specific track.

CCO Expert Recap

Faculty:

Richard E. Chaisson, MDBruce Polsky, MDJürgen K. Rockstroh, MD
  • Richard E. Chaisson, MD
  • Bruce Polsky, MD
  • Jürgen K. Rockstroh, MD

Global Epidemiology and Management Issues in Resource-Limited Settings

Track 7 of 8
Capsule Summaries
Expert Analysis

The following apply to the conference in its entirety and not to this specific track.

CCO Expert Recap

Faculty:

Michel Kazatchkine, MDMauro Schechter, MD, PhDCharles van der Horst, MD
  • Michel Kazatchkine, MD
  • Mauro Schechter, MD, PhD
  • Charles van der Horst, MD

Mother-to-Child Transmission and Management of Pediatric HIV Infection

Track 8 of 8
Capsule Summaries
Expert Analysis

The following apply to the conference in its entirety and not to this specific track.

CCO Expert Recap

Faculty:

James McIntyre, MDMarie-Louise Newell, MB, MSc, PhDKarin Nielsen, MD, MPH
  • James McIntyre, MD
  • Marie-Louise Newell, MB, MSc, PhD
  • Karin Nielsen, MD, MPH

CCO Slidesets

Update From the 2006 International AIDS Conference

Download the Slideset


Format: Microsoft PowerPoint (.ppt) | File size: 2.92 MB


Update From Toronto: Advances in the Management of Treatment-Experienced Patients

Download the Slideset


Format: Microsoft PowerPoint (.ppt) | File size: 1.42 MB


Expert Highlights (mp3)

Listen to the experts summarize the most important data from the Toronto meeting with our exclusive CCO Podcasts!

These audio files are in mp3 format. To listen to the audio, simply click "Download Audio." You must be logged onto the clinicaloptions.com site to listen to or download the mp3 files.

W. David Hardy, MD headshot

W. David Hardy, MD, reports short-term safety and efficacy data from phase II studies of maraviroc and vicriviroc, investigational CCR5 antagonists and contenders to be the next novel class of HIV therapeutics to reach clinical practice. (5 minutes)

 Download Audio
Joseph J. Eron, Jr., MD headshot

Joseph J. Eron, Jr., MD, examines data on lopinavir/ritonavir monotherapy and considers the apparent risks and benefits of this experimental treatment simplification strategy compared with conventional use of HAART. (6 minutes)

 Download Audio
Joel E. Gallant, MD, MPH headshot

Joel E. Gallant, MD, MPH, discusses the findings of a series of major clinical trials evaluating antiretroviral treatment options for use in first-line therapy for patients with HIV infection. (6 minutes)

 Download Audio
Charles van der Horst, MD headshot

Charles van der Horst, MD, explores provocative new reports on the relationship between herpes simplex virus infection and risk of HIV transmission, and their implications for HIV prevention programs. (3 minutes)

 Download Audio
Judith S. Currier, MD, MSc headshot

Judith S. Currier, MD, MSc, reviews data from Zambia and Thailand describing outcomes observed in women treated with NNRTI-containing therapy following receipt of nevirapine during pregnancy. (4 minutes)

 Download Audio
Mark A. Wainberg, PhD headshot

Mark A. Wainberg, PhD, explains why he thinks integrase inhibitors may prove to be among the major scientific breakthroughs in management of HIV disease to be reported at this conference. (6 minutes)

 Download Audio
Jürgen K. Rockstroh, MD headshot

Jürgen K. Rockstroh, MD, considers the implications of a new study from Germany, involving patients with acute HIV infection, for use of antiretroviral therapy in people who present with primary infection. (4 minutes)

 Download Audio
Mark A. Wainberg, PhD headshot

Mark A. Wainberg, PhD, Co-Chair of the XVI International AIDS Conference, speaks about his hopes for how the Toronto meeting will galvanize support for treatment access programs for people living with HIV/AIDS in resource-limited settings. (3 minutes)

 Download Audio
Richard E. Chaisson, MD headshot

Richard E. Chaisson, MD, discusses new evidence from Rio de Janeiro, Brazil, demonstrating that use of HAART plus preventive therapy for TB is more effective than either intervention alone in reducing the incidence of TB among HIV-infected patients. (6 minutes)

 Download Audio
Sally Hodder, MD headshot

Sally Hodder, MD, summarizes data from the ALIVE cohort showing that while HAART has reduced the incidence of community-acquired pneumonia in intravenous drug users, this patient group remains at high risk. (4 minutes)

 Download Audio

Additional Conference Coverage Links

www.kaisernetwork.org – Official online webcaster of the XVI International AIDS Conference

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

CAPSULE SUMMARY:

Receipt of Stavudine Plus Didanosine and Receipt of Nelfinavir Combined With Zidovudine/Lamivudine Associated With Lipoatrophy in ACTG 384

Patients receiving first-line antiretroviral therapy with didanosine plus stavudine, or nelfinavir combined with zidovudine/lamivudine, experienced significantly larger decrease in limb fat than patients receiving zidovudine/lamivudine plus efavirenz after 144 weeks of treatment.

CLICK HERE TO KEEP READING

CLICK HERE FOR RELATED CAPSULE SUMMARIES